You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Riluzole Prodrugs for Melanoma and ALS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: 102

    We have discovered a novel Type IIb prodrug of riluzole, trigriluzole (FC-4157, BVH-4157), which has the potential to substantially improve therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action. While riluzole has shown promising efficacy in treating melanoma in patients, trigrilluzole is andgt;20X more potent than riluzo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a urine test for the early detection of liver cancer

    SBC: JBS SCIENCE INC            Topic: 102

    Development of a urine test for the early detection of liver cancer The need to develop an effective method for detecting liver cancer is urgent. HCC, a primary liver cancer, is the third leading cause of cancer deaths worldwide and the fastest rising cancer in US. HCC has a 5-year survival rate of less than 15%, if detected early, the survival rate can be as high as 40%. The survival rate drops s ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    Project Summary This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA, Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired with a proprietary in-house β-lactamase inhibitor VNRX-5133 (BLI) to protect ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II

    SBC: CHROMOLOGIC LLC            Topic: NIAID

    Abstract In response to PA-15-065, the broad long-term goal of this project is to develop a portable radiation biodosimeter to be used at the point-of-care (POC) for assessing precise radiation exposure and susceptibility for acute radiation syndrome (ARS) within the first 7 days of exposure starting with ~250 µL of blood collected from a finger stick and a turnaround time (TAT) of less than 40 m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis

    SBC: Epigen Biosciences, Inc.            Topic: 400

    SummaryThe ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases, such as diabetic nephropathy (DN), that normally develop fibrosis, lead to end stage renal disease and require renal replacement therapy. DN is a complication of diabetes and is characterized by thickening of the glomerular basement membrane and mesangial expansion, with progression into ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma

    SBC: Oncoceutics, Inc.            Topic: 102

    Project Summary We propose a two-arm adaptive Phase II clinical trial to evaluate ONC201, a selective antagonist of the G protein-coupled receptor (GPCR) dopamine receptor domain 2 (DRD2), in recurrent glioblastoma (GBM) and diffuse midline glioma associated with very poor prognoses and limited treatment options. DRD2 is overexpressed in high grade gliomas and controls Akt/ERK signaling pathways. ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain

    SBC: AFASCI, INC.            Topic: NINDS

    7. PROJECT SUMMARY Neuropathic pain remains a poorly managed medical condition affecting more than 1.5 billion people worldwide. Over 20 million people suffered from diabetic neuropathy and neuropathic pain in the US alone in 2015. The current standard of care is insufficient. Topical applications and systemic treatment with existing analgesics, including opioids, leave millions suffering. More th ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Phase IIB: Exploratory Clinical trials for The V Needle

    SBC: HEMOTEK            Topic: 400

    Hemodialysis (HD) is generally perceived as a safe, benign, procedure. But if venous needle dislodgement (VND) occurs during dialysis and the machine fails to detect it, within minutes the blood loss can be catastrophic, and even fatal. It is estimated that 400 dialysis patients suffer a dislodgement episode every week in the US. [3] In a Phase I/Phase II SBIR partnership with our clinical and med ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Prospective evaluation of a surgical solution for breast cancer-associated lymphedema

    SBC: Fibralign Corporation            Topic: 102

    Project Summary/Abstract Prospective evaluation of a surgical solution for breast cancer-associated lymphedema The proposed project will complete remaining key research and technology requirements that are needed to commercialize a ground-breaking interventional device for treating secondary lymphedema -- a chronic and debilitating disease that currently has no cure and impacts an estimated 15-30% ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain

    SBC: PEPTIDE LOGIC LLC            Topic: NIDA

    PROJECT SUMMARYPain management poses significant clinical challenges due to its very high prevalencethe diversity of patients and underlying mechanismsand the lack of safe and effective treatment optionsApproximatelymillion Americans experience acute post operative painwhereas aboutmillion US adults suffer from chronic painOpioids remain the most effective class of analgesics for moderate to sever ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government